Dare Bioscience Investor Presentation Deck
Daré Financial Highlights
Snapshot:
Cash and equivalents 6/30/22: $32.1 M
Common shares o/s (8/8/22): 84.7 M
Warrants o/s: 1.6 M
Recent Updates:
3Q-22 through 8/8/22: $18.0 M cash received as
described below
Organon global license agreement for XACIATO™:
O 2Q-22: agreement became effective
3Q-22: $10.0 M upfront payment received
4Q-22: expected U.S. commercial launch & first
commercial sale milestone (resulting in $2.5 M
payable to Daré)
O
3Q-22 through 8/8/22: $8.0 M received under existing
grant for DARE-LARC1
Funding sources:
•Since inception, we have raised cash through sale of equity securities, M&A transactions, warrant and option exercises, non-
dilutive grants, and license fees
•We endeavor to be creative and opportunistic in seeking capital required to advance our candidates, and to be efficient in use
of such capital
14View entire presentation